author-photo

Isamu Okamoto

Kyushu University
Kindai University
Kumamoto University

548

Papers

18949

Citations

Citation Trend

Filter By

Papers (548) Sort By

Journal Conference Others

97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

2021 Translational lung cancer research
Show All
- Source
- Cite
- Save
Citations (1)
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (11)
MO37-6 Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)